
Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial
Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company focused on developing innovative therapies for hearing loss disorders, has successfully completed patient enrollment for the first cohort in its…












